TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Blood Norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Blood Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Blood Pancreatic Polypeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Hypoglycemia Symptom Recognition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of graft acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mania Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiological Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Difficulties in Emotion Regulation Scale (DERS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence with care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with Pre-eclampsia requiring delivery prior to 37 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: changes of pulmonary lymphatic perfusion distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: changes of coughing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Under 5 mortality
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of sick <5 years old children seeking appropriate care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of <5 years old children <-2 z weight for age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in biochemistry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in KAP questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Probability of Real-World Overall Survival (rwOS) at Month 36
Endpoint domain: Mortality/survival
Primary endpoint: Probability of Real-World Progression-Free Survival (rwPFS) at Month 36
Endpoint domain: Mortality/survival
Primary endpoint: Probability of Participants Without First Line Treatment Discontinuation or Death at Month 36
Endpoint domain: Mortality/survival
Primary endpoint: Corneal fluorescein staining score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Questionnaire Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lissamine green staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescein Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variation of the emotional recognition score (point lights test)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Myocardial 18F-FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-peptide Levels After Oral Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin Levels After Oral Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GIP and GLP-1 Levels After Oral Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Counselors awareness of psychosocial problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Management of psychosocial problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) by single-course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completely remission rate by multiple courses after single-course failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: economic outcomes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Externalizing and internalizing behavior problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical health and function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Affective status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: intestinal microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: autoimmune panels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance-progression-free survival (mPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Genotypic resistance testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to oncological treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Most common organism causing sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Transaminases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and Urine Bile Acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Hamilton Depression Rating Scale (HAMD-17) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-days point prevalence smoking abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sonographic evaluation of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of blood chemistry tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response Rate (RR) of extensive keloids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of Influenza Vaccination
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: % change from baseline in fasting serum TG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PASI-50
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of intima/media ratio in the femoral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change from baseline in forced expiratory volume in 1st second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline in FEV1/FVC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of oronasal fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Parental Acceptability of HPV vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Graft versus host disease Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Emergence Agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eliglustat plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Investigator's Global Assessment (IGA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf with itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf without itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax with itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax without itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saccadic eye movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hand tapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reaction times using a button box
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gait measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mini Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean VMAT2 Functional Binding Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline in the Total Score of the Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectable fluorescence in brain tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Richmond Agitation Sedation Scale (RASS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Motor response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of recommended surveillance intervals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of subjects improved on CGI of Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Monocular Uncorrected Visual Acuity of 20/40 or Better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary miRNA profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PANDiet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Smell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to androgen independent disease (AID)
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of significant clinical degradation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hair Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on ASIA Impairment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg positive rate in newborns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in mean IOP after 7 days treatment vs baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Griffith Mental Development Scale (GMDS) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence, severity and duration of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of total and direct bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Numeric Rating Scales (NRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Proportion of potentially inappropriate medications prescribed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Root Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: change in clinical decision following ESI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Serum Corrected Calcium Concentration Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Heart Rate at End of Study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of positive drug patch test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron overload: Ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in oxidative stress markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from displacement maximum peak (seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Time to reach maximum peak (seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Total manipulation time (seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Katz Index of Independence in Activities of Daily Living (ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pediatric Quality of Life Inventory (PedsQL). Version 4.0- Parent Report for Toddlers (Ages 2-4)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Objective Response Rate (ORR; Complete Response + Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of single oral dose of GW679769 in healthy subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of single oral dose of GW679769 in healthy subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance for Changes in ORi Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Specificity for Changes in ORi Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity for Changes in ORi Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of treatment related-adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of treatment with 177Lu-CYT-500
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of acute rejection and/or positive viremia for CMV
Endpoint domain: Adverse events/effects
Primary endpoint: absolute number of dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of cells producing cytokines in dendritic cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: absolute number of subpopulations of T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Unified Dyskinesia Rating Scale (UDysRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successfulness of the surgical procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Compliance rate
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Change in PCr Recovery Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment Emergent Serious Adverse Events (TE-SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Wrist function/pain/disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pyloric sphincter pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pyloric sphincter diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pyloric sphincter cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pyloric sphincter distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Testing Throughput
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Isolation Gowns Utilized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Cost per Test
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Return on Investment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma and urine 14C-BaP and 14C-BaP metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with recurrent VTEs during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: average hair shaft diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree completion rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: change in pulmonary capillary wedge pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Volumetric and dosimetric accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BIS value during general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of inpatient hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of participants with any adverse event (AEs) and any serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in the application site tolerability assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any clinically significant change from baseline in clinical laboratory parameter values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any clinically significant change from baseline in vital sign values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with any clinically significant change from baseline in electrocardiogram (ECG) findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of glomerular filtration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Negative control test for Chlamydia in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: blood alcohol content (BAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary alcohol metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response Rate at the End of 30 Day Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate at the End of 60 Day Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: reduction of ulcer rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: opening rate of thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients who can safely omit surgery
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients who have local failure
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of TNFα and chemokines in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Compliance to follow-up at 6 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance to follow-up at 1 year
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance to follow-up at 2 years
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in total neuropsychological performance after axi-cel therapy - Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in total neuropsychological performance after axi-cel therapy - Attention and Concentration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in total neuropsychological performance after axi-cel therapy - Executive Functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in total neuropsychological performance after axi-cel therapy - Hand grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-reported outcomes after axi-cel therapy - PROMIS-29 Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of women who stopped smoking postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of women who relapsed smoking postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of intent to treat under thoracoscopy vs thoracotomy procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Resolution of Bacterial Conjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Lequesne's Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain (VAS in mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Adipokine Release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes